LRRK2/NUAK1/TYK2-IN-1

LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), TYK2 and NUAK1, with IC50 values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research[1].

Product Specifications

CAS Number

[2629192-96-5]

UNSPSC

12352005

Target

AMPK; JAK; LRRK2

Type

Reference compound

Related Pathways

Autophagy; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lrrk2-nuak1-tyk2-in-1.html

Solubility

10 mM in DMSO

Smiles

FC1=CC=CC(F)=C1C2=NC3=C(C4=NNC=C4N2)C=C(F)C(C5=CC=NN=C5)=C3

Molecular Formula

C20H11F3N6

Molecular Weight

392.34

References & Citations

[1]Roland Koestler, et al. 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease. Patent WO2021048618A1.